loading page

Prognostic Significance of COX-2 Expression in Wilms' Tumor
  • Onur Ceylan,
  • Ozgur Caglar
Onur Ceylan

Corresponding Author:[email protected]

Author Profile
Ozgur Caglar
Ataturk University Faculty of Medicine
Author Profile

Abstract

Objectives: In Wilms Tumor (WT) secondary malignancies caused by the side effects of intensive treatments remain one of the important problems. Therefore, there is a need for new studies to identify low- and high-risk groups for WT and to improve the treatment regimens of children in the low-risk group. Therefore, in our study, we aimed to determine the prognostic significance of the cyclooxygenase-2 (COX-2) biomarker in WT. Materials and Methods: Our study included 24 patients diagnosed with WT between January 2010 and December 2019. The correlation between COX-2 expression and significant prognostic parameters was investigated by studying COX-2 antibody using the immunohistochemical method. Results: COX-2 expression was observed in 22 of the patients, and the expression was more evident especially in the epithelial component. There was no significant correlation between COX-2 positivity and prognostic parameters. Conclusions: In our study, no significant relationship was found between significant prognostic parameters and COX-2 expression. We think that the COX-2 pathway is effective during the development phase of WT, since COX-2 expression was observed in almost all patients, therefore it may be beneficial to add COX-2 inhibitors to the treatment, and that a sufficient number of studies should be conducted in this respect.
22 Dec 2020Submitted to International Journal of Clinical Practice
24 Dec 2020Submission Checks Completed
24 Dec 2020Assigned to Editor
29 Dec 2020Reviewer(s) Assigned
20 Jan 2021Review(s) Completed, Editorial Evaluation Pending
09 Feb 20211st Revision Received
11 Feb 2021Submission Checks Completed
11 Feb 2021Assigned to Editor
15 Feb 2021Reviewer(s) Assigned
06 Mar 2021Review(s) Completed, Editorial Evaluation Pending
07 Mar 2021Editorial Decision: Accept